SWOT Analysis for Halozyme Therapeutics Inc.

Add SWOT widget to your site/app

High DVM Mid and Small Caps (subscription)
Stocks in Buy Zone with High Momentum Score Last Month
Strong Performer, Getting Expensive (DVM)
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV
Companies with 10% increase in share price over three months, with rising net profit growth
Consistent Highest Return Stocks over Five Years - Nifty500
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Big Gainers in Share Price with Good Net Profit Growth
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 10 Years
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Near 52 Week High
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Increasing Revenue every quarter for the past 3 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Increasing profits every quarter for the past 3 quarters
Top Gainers
Volume Shockers
High Volume, High Gain
Stocks Outperforming their Industry Price Change in the Quarter